EconPapers    
Economics at your fingertips  
 

Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer’s disease mouse model

Laura K. Hamilton, Gaël Moquin-Beaudry, Chenicka L. Mangahas, Federico Pratesi, Myriam Aubin, Anne Aumont, Sandra E. Joppé, Alexandre Légiot, Annick Vachon, Mélanie Plourde, Catherine Mounier, Martine Tétreault and Karl J. L. Fernandes ()
Additional contact information
Laura K. Hamilton: Université de Montréal
Gaël Moquin-Beaudry: Université de Montréal
Chenicka L. Mangahas: Université de Montréal
Federico Pratesi: Université de Montréal
Myriam Aubin: CIUSSS de l’Estrie-CHUS
Anne Aumont: Université de Montréal
Sandra E. Joppé: Université de Montréal
Alexandre Légiot: Université de Québec à Montréal (UQAM)
Annick Vachon: CIUSSS de l’Estrie-CHUS
Mélanie Plourde: CIUSSS de l’Estrie-CHUS
Catherine Mounier: Université de Québec à Montréal (UQAM)
Martine Tétreault: Université de Montréal
Karl J. L. Fernandes: Université de Montréal

Nature Communications, 2022, vol. 13, issue 1, 1-17

Abstract: Abstract The defining features of Alzheimer’s disease (AD) include alterations in protein aggregation, immunity, lipid metabolism, synapses, and learning and memory. Of these, lipid abnormalities are the least understood. Here, we investigate the role of Stearoyl-CoA desaturase (SCD), a crucial regulator of fatty acid desaturation, in AD pathogenesis. We show that inhibiting brain SCD activity for 1-month in the 3xTg mouse model of AD alters core AD-related transcriptomic pathways in the hippocampus, and that it concomitantly restores essential components of hippocampal function, including dendritic spines and structure, immediate-early gene expression, and learning and memory itself. Moreover, SCD inhibition dampens activation of microglia, key mediators of spine loss during AD and the main immune cells of the brain. These data reveal that brain fatty acid metabolism links AD genes to downstream immune, synaptic, and functional impairments, identifying SCD as a potential target for AD treatment.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-29506-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29506-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-29506-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29506-y